By PPN News Staff
A once-daily, single-tablet regimen (STR) containing darunavir (Prezista, Janssen), cobicistat (Tybost, Gilead), emtricitabine (Emtriva, Gilead) and tenofovir alafenamide (Vemlidy, Gilead) (D/C/F/TAF) had a low cumulative virologic rebound rate and a high virologic suppression rate at 24 weeks in HIV-1–positive, virologically suppressed adults who switched from a standard boosted protease inhibitor (PI) regimen, according to a presentation at the 2017 annual International
AUGUST 1, 2017